Skip to main content
. 2015 Dec 29;5(2):182–191. doi: 10.1002/cam4.576

Figure 3.

Figure 3

Estimated median treatment duration of metastatic castration‐resistant prostate cancer (mCRPC) drugsa in the 2000–2013 commercial claims cohort. (A) LOT1; (B) LOT2. LOT1, first line of treatment; LOT2, second line of treatment. Horizontal line = median; box = 25% and 75% quartiles, whisker = minimum and maximum values. aSipuleucel‐T was not included because of the fixed‐duration treatment course.